Cargando…
Evaluation of off-label rapamycin use to promote healthspan in 333 adults
Rapamycin (sirolimus) is an FDA-approved drug with immune-modulating and growth-inhibitory properties. Preclinical studies have shown that rapamycin extends lifespan and healthspan metrics in yeast, invertebrates, and rodents. Several physicians are now prescribing rapamycin off-label as a preventat...
Autores principales: | Kaeberlein, Tammi L., Green, Alan S., Haddad, George, Hudson, Johnny, Isman, Anar, Nyquist, Andy, Rosen, Bradley S., Suh, Yousin, Zalzala, Sajad, Zhang, Xingyu, Blagosklonny, Mikhail V., An, Jonathan Y., Kaeberlein, Matt |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10187519/ https://www.ncbi.nlm.nih.gov/pubmed/37191826 http://dx.doi.org/10.1007/s11357-023-00818-1 |
Ejemplares similares
-
Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice
por: Bitto, Alessandro, et al.
Publicado: (2016) -
Rapamycin in aging and disease: maximizing efficacy while minimizing side effects
por: Johnson, Simon C., et al.
Publicado: (2016) -
Caffeine extends life span, improves healthspan, and delays age-associated pathology in Caenorhabditis elegans
por: Sutphin, George L, et al.
Publicado: (2012) -
Protein Kinase C Downregulation upon Rapamycin Treatment Attenuates Neuroinflammation and Mitochondrial Disease
por: Grillo, Anthony, et al.
Publicado: (2020) -
Rapamycin enhances survival in a Drosophila model of mitochondrial disease
por: Wang, Adrienne, et al.
Publicado: (2016)